Document is current
Any future updates will be listed below
-
Authors
Tymms, Kathleen https://orcid.org/0000-0002-6340-8105
Butcher, Belinda E. https://orcid.org/0000-0002-1415-4065
Sletten, Tracey L. https://orcid.org/0000-0002-0005-7838
Smith, Tegan https://orcid.org/0000-0002-2944-9712
O’Sullivan, Catherine https://orcid.org/0000-0003-0564-9768
Littlejohn, Geoffrey https://orcid.org/0000-0002-7896-055X
Sadler, Ricky
Tronnberg, Rebecca
Griffiths, Hedley https://orcid.org/0000-0001-5869-797X
,
-
Funding
Funding for this research was provided by:
novartis pharmaceuticals australia pty ltd (.)
- License Information
-
More Information
Article History
Received: 8 July 2021
Revised: 27 September 2021
Accepted: 30 September 2021
First Online: 26 November 2021
Declarations
:
: This study was approved by University of New South Wales (UNSW) Human Research Ethics Committee (HREC) (HC180712).
: The activities of OPAL Rheumatology Ltd have received overarching ethics approval from the UNSW HREC, based on a patient opt-out arrangement (HC17799). This research protocol was approved by the UNSW HREC (HC180712).
: KT, TLS, GL and HG report no conflicts of interest. RT and RS are employees of Novartis Pharmaceuticals Australia Pty Ltd. TS and CO are employees of OPAL Rheumatology Ltd. BEB is an independent statistician who was contracted by OPAL Rheumatology Ltd to perform the analysis. OPAL independently developed the study design, protocol, statistical analysis plan and data analysis. We do invite the appropriate medical employee or real-world evidence team member from the sponsoring company to give input and review of the final manuscript. The decision to publish the results from this study was not dependent on the results obtained nor influenced by the sponsoring company and interpretation of the data remains with the rheumatologist/principal investigator on the study.
